Cantor Fitzgerald restated their overweight rating on shares of Immunome (NASDAQ:IMNM – Get Rating) in a report released on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Immunome’s FY2023 earnings at ($1.58) EPS. Separately, Chardan Capital decreased their price objective on shares of Immunome from $9.00 to $8.00 and set a buy rating […]
Immunome, Inc. (NASDAQ:IMNM – Get Rating) – Equities research analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Immunome in a research note issued on Monday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($1.58) for the year. Cantor Fitzgerald has a “Overweight” […]
Immunome, Inc. (NASDAQ:IMNM – Get Rating) – Stock analysts at Chardan Capital cut their FY2023 earnings estimates for Immunome in a research note issued to investors on Tuesday, May 9th. Chardan Capital analyst M. Barcus now anticipates that the company will post earnings of ($0.77) per share for the year, down from their prior estimate […]
Immunome, Inc. , a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported. | May 5, 2023
Immunome, Inc. (NASDAQ:IMNM – Get Rating) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 183,200 shares, an increase of 12.6% from the March 31st total of 162,700 shares. Based on an average daily trading volume, of 40,600 shares, the days-to-cover ratio is […]